Literature DB >> 919112

Prevention of postoperative deep-vein thrombosis by low-dose heparin in urological surgery. A double-blind, randomised study.

M Kutnowski, M Vandendris, R Steinberger, M Kraytman.   

Abstract

The efficacy of low-dose heparin in preventing deep-vein thrombosis (D. V. T.) after urological surgery was investigated in a double-blind trial. Thromboses were detected by the 125I-labelled fibrinogen technique. The incidence of D. V. T. was 36% in the control group (25 patients) and 9% in the treated group (22 patients) (p less than 0.05). Contrary to the current opinion this form of prophylaxis was effective following open prostatectomy.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 919112     DOI： 10.1007/bf00256865

Source DB:  PubMed          Journal:  Urol Res        ISSN： 0300-5623


  13 in total

1.  Heparin as an antithrombotic agent. Low-dose prophylaxis.

Authors:  S Wessler
Journal:  JAMA       Date:  1976-07-26       Impact factor: 56.272

2.  [Preventive treatment of thromboembolic postoperative complications in urology using subcutaneous calcium heparinate].

Authors:  A Xerri; J P Deburge; J Aubert; G Weisgerber
Journal:  J Urol Nephrol (Paris)       Date:  1974-03

3.  Small doses of subcutaneous sodium heparin in preventing deep venous thrombosis after major surgery.

Authors:  A N Nicolaides; P A Dupont; S Desai; J D Lewis; J N Douglas; H Dodsworth; G Fourides; R J Luck; C W Jamieson
Journal:  Lancet       Date:  1972-10-28       Impact factor: 79.321

4.  Low doses of heparin in prevention of deep-vein thrombosis.

Authors:  V V Kakkar; E S Field; A N Nicolaides; P T Flute
Journal:  Lancet       Date:  1971-09-25       Impact factor: 79.321

5.  Prevention of postoperative deep-vein thrombosis with perioperative subcutaneous heparin.

Authors:  H T Williams
Journal:  Lancet       Date:  1971-10-30       Impact factor: 79.321

6.  125-I-labelled fibrinogen test adapted for routine screening for deep-vein thrombosis.

Authors:  V V Kakkar; A N Nicolaides; J T Renney; J R Friend; M B Clarke
Journal:  Lancet       Date:  1970-03-14       Impact factor: 79.321

7.  Anticoagulants in open prostatectomies.

Authors:  W S Jasper
Journal:  J Urol       Date:  1977-01       Impact factor: 7.450

8.  [Prevention of thrombo-embolic complications in urology using sub-cutaneous calcium heparinate (author's transl)].

Authors:  J Aubert; P Brisacier
Journal:  J Urol Nephrol (Paris)       Date:  1975-03

9.  Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial.

Authors: 
Journal:  Lancet       Date:  1975-07-12       Impact factor: 79.321

10.  Diagnosis of established deep vein thrombosis with the 125 I fibrinogen uptake test.

Authors:  N L Browse; W F Clapham; D N Croft; D J Jones; M L Thomas; J O Williams
Journal:  Br Med J       Date:  1971-11-06
View more
  4 in total

1.  Prevention of postoperative deep-vein thrombosis by low-dose heparin in open prostatectomy.

Authors:  M Vandendris; M Kutnowski; B Futeral; X Gianakopoulos; M Kraytman; W Gregoir
Journal:  Urol Res       Date:  1980

Review 2.  Hemostatic alterations in cancer patients.

Authors:  F R Rickles; M Levine; R L Edwards
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

3.  Prophylaxis of postoperative venous thrombosis in a controlled trial comparing dextran 70 and low-dose heparin.

Authors:  D Bergqvist; T Hallböök
Journal:  World J Surg       Date:  1980       Impact factor: 3.352

4.  American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.

Authors:  David R Anderson; Gian Paolo Morgano; Carole Bennett; Francesco Dentali; Charles W Francis; David A Garcia; Susan R Kahn; Maryam Rahman; Anita Rajasekhar; Frederick B Rogers; Maureen A Smythe; Kari A O Tikkinen; Adolph J Yates; Tejan Baldeh; Sara Balduzzi; Jan L Brożek; Itziar Etxeandia- Ikobaltzeta; Herman Johal; Ignacio Neumann; Wojtek Wiercioch; Juan José Yepes-Nuñez; Holger J Schünemann; Philipp Dahm
Journal:  Blood Adv       Date:  2019-12-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.